A prothrombotic state is reported with severe COVID-19 infection, which can manifest in
venous and arterial thrombotic events. Coagulopathy is reflective of more severe disease …

Introduction COVID-19 disease progresses through a number of distinct phases. The
management of each phase is unique and specific. The pulmonary phase of COVID-19 is …

Given the evidence for a hyperactive platelet phenotype in COVID-19, we investigated
effector cell properties of COVID-19 platelets on endothelial cells (ECs). Integration of EC …

Earlier variants of SARS-CoV-2 have been associated with hypercoagulability and an
extensive formation of fibrin amyloid microclots, which are considered to contribute to the …

Abstract Background Type 2 Diabetes Mellitus (T2DM) is a well-known comorbidity to
COVID-19 and coagulopathies are a common accompaniment to both T2DM and COVID-19 …

Infection by SARS-CoV-2 is associated with a high risk of thrombosis. The laboratory
documentation of hypercoagulability and impaired fibrinolysis remains a challenge. Our aim …

Coronavirus disease 2019 (COVID-19)-associated coagulopathy (CAC), characterized by
hypercoagulability and an increased risk of thrombotic complications, is an important …

In addition to preserving homeostasis and contributing to immunity, platelets may exhibit a
dysregulated state1, 2 in acute respiratory distress syndrome (ARDS) and potentially …

There is increasing evidence that novel coronavirus disease 2019 (COVID-19) leads to a
significant coagulopathy, a phenomenon termed “COVID-19 associated coagulopathy.” …

Hypercoagulability in coronavirus disease 2019 (COVID-19) may aggravate disease
severity during hospitalization but the reported survival benefits from anticoagulation (AC) …